sorrento
therapeutics
releases
positive
results
phase
trial
resiniferatoxin
rtx
epidural
cancer
patients
reported
intractable
pain
seventeen
subjects
advanced
cancer
pain
received
epidural
rtx
mcg
dose
limiting
toxicities
reported
majority
patients
reported
meaningful
pain
reduction
baseline
sorrento
expects
submit
fda
request
proceed
phase
clinical
trial
orphan
indication
imminently
san
diego
globe
newswire
sorrento
therapeutics
nasdaq
srne
sorrento
announced
public
release
results
multicenter
phase
study
evaluate
safety
mtd
epidural
resiniferatoxin
injection
treatment
intractable
cancer
pain
annual
pain
therapeutics
summit
held
virtually
september
data
presented
srdjan
nedeljkovic
md
associate
professor
anesthesia
harvard
medical
school
brigham
women
hospital
extremely
encouraged
results
initial
study
even
patients
high
levels
pain
rtx
given
via
epidural
injection
found
reduce
pain
intensity
without
adverse
safety
consequences
said
associate
professor
anesthesia
srdjan
nedeljkovic
department
anesthesiology
perioperative
pain
medicine
brigham
women
hospital
harvard
medical
school
patient
population
intractable
pain
respond
standard
therapeutic
approaches
including
opioids
addition
rtx
management
patients
intractable
cancer
pain
offers
prospect
reducing
suffering
improving
quality
life
underserved
patient
population
multicenter
study
enrolled
adults
intractable
moderate
severe
cancer
pain
subjects
treated
epidural
administration
rtx
escalating
dose
level
cohorts
ranging
µg
µg
ml
saline
seven
cohorts
first
participant
cohort
served
sentinel
subject
first
two
dosing
cohorts
µg
µg
included
one
subject
subsequent
cohorts
proceeded
three
subjects
µg
enrollment
dose
escalation
cohorts
completed
subjects
receiving
rtx
women
men
median
age
years
range
years
baseline
numerical
pain
rating
scale
nprs
average
score
mean
standard
deviation
baseline
nprs
worst
score
mean
toxicities
reported
dose
escalation
completed
ug
frequently
reported
adverse
event
transient
pain
described
subjects
pain
managed
traditional
pain
medications
day
rtx
injection
typically
pain
following
injection
subsided
assessment
resolved
within
hours
subjects
transient
reversible
adverse
events
reported
least
two
subjects
nausea
vomiting
headache
total
serious
adverse
events
saes
reported
none
deemed
investigator
related
rtx
treatment
adverse
events
attributed
underlying
cancer
diagnosis
clinical
efficacy
ce
assessed
three
efficacy
levels
defined
decrease
pain
respectively
three
consecutive
days
original
baseline
nprs
score
positive
outcome
observed
lowest
dose
rtx
administered
ug
efficacy
point
relationship
observed
majority
responders
ug
ug
dose
levels
subjects
achieved
prespecified
efficacy
using
nprs
scores
day
results
rtx
doses
pooled
shown
percentage
decrease
pain
average
pain
worst
pain
reduction
baseline
reduction
baseline
reduction
baseline
pk
data
revealed
detectable
drug
plasma
subjects
minimally
detectable
levels
rtx
seen
subjects
case
initial
time
point
rtx
administration
given
epidural
injection
doses
ug
preliminary
clinical
pain
improvement
observed
phase
based
results
though
protocol
allowed
exploration
mcg
dose
indication
dose
beyond
mcg
deemed
necessary
qualify
safety
clinically
meaningful
efficacy
drug
preliminary
data
support
study
epidural
rtx
broader
patient
population
would
considered
moderate
severe
pain
associated
cancer
orphan
indication
access
poster
associated
scientific
presentation
please
visit
sorrento
investor
relations
site
sorrento
intends
rapidly
advance
larger
scale
trials
expects
submit
request
proceed
multicenter
blinded
controlled
phase
trial
fda
upcoming
weeks
resiniferatoxin
rtx
thousand
times
hotter
pure
capsaicin
billion
scoville
units
versus
high
affinity
afferent
pain
nerves
resiniferatoxin
binds
receptors
selectively
ablates
nerve
endings
responsible
pain
signals
experienced
delivered
peripherally
joint
space
transient
nerve
ending
ablation
effect
profound
clinical
benefits
lasting
months
years
shown
canine
multicenter
dose
escalation
phase
study
assess
safety
define
maximally
tolerated
dose
resiniferatoxin
administered
via
epidural
route
reduction
moderate
severe
pain
signal
intensity
associated
advanced
cancer
phase
study
protocol
cohorts
patients
received
increasing
doses
resiniferatoxin
maximum
tolerated
dose
achieved
primary
objective
study
evaluate
safety
resiniferatoxin
identify
recommended
phase
dose
secondary
objective
assess
preliminary
efficacy
resiniferatoxin
measured
assessing
changes
intensity
pain
using
nprs
score
widely
used
proprietary
validated
pain
scale
rtx
approved
clinical
use
regulatory
authorities
safety
efficacy
established
information
trial
found
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completing
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
expectations
sorrento
subsidiaries
technologies
product
candidates
including
limited
resiniferatoxin
rtx
clinical
potential
rtx
timing
commencing
larger
scale
trials
rtx
timing
completion
submission
request
proceed
phase
trial
rtx
possibility
proceeding
phase
trial
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
affiliates
partners
technologies
prospects
including
limited
rtx
risks
related
seeking
regulatory
approvals
conducting
obtaining
results
clinical
trials
costs
associated
clinical
trials
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
clinical
commercial
success
rtx
viability
success
using
rtx
treatments
certain
therapeutic
areas
including
treatment
intractable
pain
associated
cancer
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
media
investor
relations
alexis
nahama
svp
head
rtx
program
telephone
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
inc
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
